Novel agents in mantle cell lymphoma

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 2, 2012, Pages 191-200

  Noel, Marcus S ^a   Friedberg, Jonathan W ^a   Barr, Paul M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

B cell receptor; mantle cell lymphoma; novel agents

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALISERTIB; AVL 292; BMN 673; BRUTON TYROSINE KINASE INHIBITOR; CD20 ANTIBODY; CDY 1127; CEP 9722; DACETUZUMAB; ENZASTAURIN; FLAVOPIRIDOL; FOSTAMATINIB; GSK 3; IBRUTINIB; INCB 16562; MONOCLONAL ANTIBODY; NAVITOCLAX; OBATOCLAX; OFATUMUMAB; PANOBINOSTAT; PROTEIN TYROSINE KINASE INHIBITOR; RANDEPSIN; SAR 245409; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VELTIZUMAB; VORINOSTAT;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER PROGNOSIS; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG EMBOLISM; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SMALL INTESTINE OBSTRUCTION; SOLID TUMOR; SPLEEN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84862232014     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.04.001     Document Type: Review

References (40)

1. P. Martin, A. Chadburn, and P. Christos Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. [Research Support, Non-U.S. Gov't] 19 7 2008 Jul 1327 1330 (Pubitemid 351911966)
2. F.K. Stevenson, S. Krysov, and A.J. Davies B-cell receptor signaling in chronic lymphocytic leukemia Blood 118 16 2011 Oct 20 4313 4320
3. P. Perez-Galan, M. Dreyling, and A. Wiestner Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Blood. [Research Support, N.I.H., Intramural Review] 117 1 2011 Jan 6 26 38
4. C. Pighi, T.L. Gu, and I. Dalai Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling Cell Oncology (Dordr). [Research Support, Non-U.S. Gov't] 34 2 2011 Apr 141 153
5. A. Rinaldi, I. Kwee, and M. Taborelli Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma British Journal of Haematology. [Research Support, Non-U.S. Gov't] 132 3 2006 Feb 303 316 (Pubitemid 43381537)
6. J.W. Friedberg, J. Sharman, and J. Sweetenham Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood. [Clinical Trial, Phase I Clinical Trial, Phase II Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 115 13 2010 Apr 1 2578 2585
7. L.A. Honigberg, A.M. Smith, and M. Sirisawad The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proceedings of the National Academy of Sciences of the United States of America 107 29 2010 Jul 20 13075 13080
8. S.E. Herman, A.L. Gordon, and E. Hertlein Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Blood. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 117 23 2011 Jun 9 6287 6296
9. N. Fowler, J.P. Sharman, and S.M. Smith The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study ASH Annual Meeting Abstracts 2010 116 21 November 19, 2010 964
10. D. Chantry, A. Vojtek, and A. Kashishian p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes The Journal of Biological Chemistry. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 272 31 1997 Aug 1 19236 19241 (Pubitemid 27337713)
11. B.J. Lannutti, S.A. Meadows, and S.E. Herman CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 2 2011 Jan 13 591 594
12. J. Hoellenriegel, S.A. Meadows, and M. Sivina The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia Blood. [Research Support, Non-U.S. Gov't] 118 13 2011 Sep 29 3603 3612
13. B. Kahl, J.C. Byrd, and I.W. Flinn Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma ASH Annual Meeting Abstracts 2010 116 21 November 19, 2010 1777
14. I.W. Flinn, M.T. Schreeder, and N. Wagner-Johnston A phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in combination with rituximab and/or bendamustine in patients with relapsed or refractory B-cell malignancies ASH Annual Meeting Abstracts 2010 116 21 November 19, 2010 2832
15. M. Rudelius, S. Pittaluga, and S. Nishizuka Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma Blood. [Research Support, N.I.H., Intramural] 108 5 2006 Sep 1 1668 1676 (Pubitemid 44316136)
16. H. Hirai, H. Sootome, and Y. Nakatsuru MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo Molecular Cancer Therapeutics. [Research Support, Non-U.S. Gov't] 9 7 2010 Jul 1956 1967
17. C.B. Reeder, and S.M. Ansell Novel therapeutic agents for B-cell lymphoma: developing rational combinations Blood. [Review] 117 5 2011 Feb 3 1453 1462
18. F. Morschhauser, J.F. Seymour, and H.C. Kluin-Nelemans A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. [Clinical Trial, Phase II Research Support, Non-U.S. Gov't] 19 2 2008 Feb 247 253 (Pubitemid 351209293)
19. L.V. Pham, A.T. Tamayo, and C. Li Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications Molecular Cancer Therapeutics. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 9 7 2010 Jul 2026 2036
20. F. Baran-Marszak, M. Boukhiar, and S. Harel Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma Haematologica. [Clinical Trial Multicenter Study Research Support, Non-U.S. Gov't] 95 11 2010 Nov 1865 1872
21. E. Derenzini, M. Lemoine, and E. Brighenti The small molecule JAK1/JAK2 inhibitor INCB16562 shows single agent activity and strongly synergizes with Bcl-2 inhibitors in lymphoma ASH Annual Meeting Abstracts 2011 118 21 November 18, 2011 2731
22. C. Touzeau, C. Dousset, and L. Bodet ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. [Research Support, Non-U.S. Gov't] 17 18 2011 Sep 15 5973 5981
23. P. Perez-Galan, G. Roue, and N. Villamor The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak Blood. [Evaluation Studies Research Support, Non-U.S. Gov't] 109 10 2007 May 15 4441 4449 (Pubitemid 46743414)
24. E. Beltran, V. Fresquet, and J. Martinez-Useros A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma Proceedings of the National Academy of Sciences of the United States of America. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 108 30 2011 Jul 26 12461 12466
25. C. Tse, A.R. Shoemaker, and J. Adickes ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Research 68 9 2008 May 1 3421 3428
26. B.D. Cheson Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Review] 28 21 2010 Jul 20 3525 3530
27. G. Nightingale Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia The Annals of Pharmacotherapy 45 10 2011 Oct 1248 1255
28. A. Hagenbeek, O. Gadeberg, and P. Johnson First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial Blood. [Clinical Trial, Phase I Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov't] 111 12 2008 Jun 15 5486 5495
29. R. Advani, A. Forero-Torres, and R.R. Furman Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Clinical Trial, Phase I Multicenter Study] 27 26 2009 Sep 10 4371 4377
30. L. Alinari, B. Yu, and B.A. Christian Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma Blood. [In Vitro Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 117 17 2011 Apr 28 4530 4541
31. A.A. Lane, and B.A. Chabner Histone deacetylase inhibitors in cancer therapy Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Review] 27 32 2009 Nov 10 5459 5468
32. S. Xargay-Torrent, M. Lopez-Guerra, and I. Saborit-Villarroya Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. [Research Support, Non-U.S. Gov't] 17 12 2011 Jun 15 3956 3968
33. M. Kirschbaum, P. Frankel, and L. Popplewell Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Clinical Trial, Phase II Research Support, N.I.H., Extramural] 29 9 2011 Mar 20 1198 1203
34. V.Y. Yazbeck, D. Buglio, and G.V. Georgakis Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma Experimental Hematology 36 4 2008 Apr 443 450 (Pubitemid 351384743)
35. W. Qi, L.S. Cooke, and X. Liu Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma Biochemical Pharmacology. [Research Support, N.I.H., Extramural 81 7 2011 Apr 1 881 890
36. Session 14: signalling pathways in lymphoma. Ann Oncol. 2011 June 1, 2011; 22(Suppl. 4): iv135-iv137.
37. G. Venkataraman, T. Maududi, and F. Ozpuyan Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment Leukemia Research 30 11 2006 Nov 1377 1384 (Pubitemid 44307323)
38. T.S. Lin, K.A. Blum, and D.B. Fischer Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Clinical Trial, Phase I Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 28 3 2010 Jan 20 418 423
39. S. Kummar, R. Kinders, and M.E. Gutierrez Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. [Clinical Trial Research Support, N.I.H., Extramural] 27 16 2009 Jun 1 2705 2711
40. V.J. Weston, C.E. Oldreive, and A. Skowronska The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo Blood. [Research Support, Non-U.S. Gov't] 116 22 2010 Nov 25 4578 4587